Price | 1784€+ Login to see price |
Organism | Human |
Product Type | Tissue derived organoid |
Tissue | Pancreas |
Disease | Pancreatic cancer |
Applications
Toxicity
Small molecules
mRNA
Antibody
Cancer vaccine
Immune Cells
Immuno Oncology with TME
Cytotoxic T cell
TIL (Tumor infiltrating lymphocytes)
Regulatory T cell
Macrophage
CAF (Cancer associate fibroblast)
Our pancreatic cancer organoids exhibit a high degree of pathological similarity to patient-derived tumor tissues, expressing key pancreatic cancer markers such as ANXA1, ANXA10 and ANXA13.
Immunohistochemistry (IHC) analyses confirm that these markers are expressed in the organoids in patterns consistent with those observed in primary tumors, accurately reflecting the differentiation status and histological characteristics of the original tissue.
These pathological marker analyses demonstrate that pancreatic cancer organoids faithfully recapitulate the morphological and molecular features of patient tumors, establishing them as a reliable platform for cancer pathology research, drug development, and the evaluation of personalized therapeutic strategies.
The pancreatic cancer (PC) organoid platform provides a physiologically relevant model that reflects the genetic characteristics of patient tumors.
Whole Exome Sequencing (WES) has been performed on the organoid library, identifying key driver mutations commonly found in PC.
These genomic profiles are visualized using Oncoplots, providing clear interpretation of the genetic features of each organoid model.
With WES data already established, cancer organoids harboring specific gene mutations can be selectively utilized for targeted drug testing, mechanistic studies, and mutation-driven drug response analysis.
These organoids serve as versatile models that reflect diverse tumor characteristics such as metastasis, treatment resistance, and drug sensitivity, making them effective for evaluating both standard therapies and novel anticancer strategies.
This platform supports mutation-specific organoid selection and testing, positioning it as a powerful tool for precision oncology and the development of personalized cancer therapies.
A tailored solution for evaluating the efficacy and resistance of new drugs is available using an established pancreatic cancer (PC) organoid library.
By leveraging comprehensive drug sensitivity data, the most suitable organoid lines are selected based on the characteristics of the investigational drug, enabling precise and reliable drug testing.
Drug sensitivity tests have been conducted using Gemcitabine and Paclitaxel which are widely used in clinical cancer treatment, and drug response data has been collected from a subset of PC organoid models, comprising over 15 distinct lines.
This dataset continues to expand as additional testing is performed.
This organoid-based drug sensitivity testing platform enhances the efficiency and reliability of the drug development process and contributes to the advancement of personalized cancer treatment strategies.
